146 related articles for article (PubMed ID: 25129342)
1. Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs.
Plotkin A; Volmar CH; Wahlestedt C; Ayad N; El-Ashry D
Breast Cancer Res Treat; 2014 Sep; 147(2):249-63. PubMed ID: 25129342
[TBL] [Abstract][Full Text] [Related]
2. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype.
Shah SH; Miller P; Garcia-Contreras M; Ao Z; Machlin L; Issa E; El-Ashry D
Cancer Biol Ther; 2015; 16(11):1671-81. PubMed ID: 26186233
[TBL] [Abstract][Full Text] [Related]
3. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
Zhou Q; Atadja P; Davidson NE
Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
[TBL] [Abstract][Full Text] [Related]
5. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
6. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
8. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Sharma D; Saxena NK; Davidson NE; Vertino PM
Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Yang X; Ferguson AT; Nass SJ; Phillips DL; Butash KA; Wang SM; Herman JG; Davidson NE
Cancer Res; 2000 Dec; 60(24):6890-4. PubMed ID: 11156387
[TBL] [Abstract][Full Text] [Related]
10. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
Macaluso M; Cinti C; Russo G; Russo A; Giordano A
Oncogene; 2003 Jun; 22(23):3511-7. PubMed ID: 12789259
[TBL] [Abstract][Full Text] [Related]
11. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor.
Mazumdar A; Wang RA; Mishra SK; Adam L; Bagheri-Yarmand R; Mandal M; Vadlamudi RK; Kumar R
Nat Cell Biol; 2001 Jan; 3(1):30-7. PubMed ID: 11146623
[TBL] [Abstract][Full Text] [Related]
13. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Vesuna F; Lisok A; Kimble B; Domek J; Kato Y; van der Groep P; Artemov D; Kowalski J; Carraway H; van Diest P; Raman V
Oncogene; 2012 Jul; 31(27):3223-34. PubMed ID: 22056872
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.
Arabsolghar R; Azimi T; Rasti M
Mol Biol Rep; 2013 Mar; 40(3):2617-25. PubMed ID: 23242655
[TBL] [Abstract][Full Text] [Related]
15. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
17. Scriptaid effects on breast cancer cell lines.
Giacinti L; Giacinti C; Gabellini C; Rizzuto E; Lopez M; Giordano A
J Cell Physiol; 2012 Oct; 227(10):3426-33. PubMed ID: 22213035
[TBL] [Abstract][Full Text] [Related]
18. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
19. Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.
Shankar E; Pandey M; Verma S; Abbas A; Candamo M; Kanwal R; Shukla S; MacLennan GT; Gupta S
Mol Carcinog; 2020 Aug; 59(8):955-966. PubMed ID: 32391971
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway.
Suzuki K; Oneyama C; Kimura H; Tajima S; Okada M
J Biol Chem; 2011 May; 286(18):15698-706. PubMed ID: 21388951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
